Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14210085 | 1.00 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL2861270 | 0.89 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL12363977 | 0.86 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL14209303 | 0.86 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL19201012 | 0.86 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL2868473 | 0.85 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL27688129 | 0.85 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL1456771 | 0.85 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL27945371 | 0.85 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL2868444 | 0.85 | SLC5A2 (0.45) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1581543-A4 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| EP-1581543-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063209-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.